| Phase 12 trials |
|
Phase 1
|
NCT04121286 |
Jul 2020 → Jun 2022 |
breast cancer, colorectal cancer, esophageal squamous cell carcinoma, head and neck squamous cell carcinoma +2 |
Allist Pharmaceuticals, Inc. |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT04045496 |
Sep 2019 → Dec 2022 |
breast cancer, colorectal cancer, esophageal squamous cell carcinoma, head and neck squamous cell carcinoma +2 |
Jacobio Pharmaceuticals Co., Ltd. |
Completed
|
No outcome recorded
|
| Phase 1/22 trials |
|
Phase 1/2
|
NCT05288205 |
Apr 2022 → Mar 2026 overdue |
acute myeloid leukemia, KRAS gene mutation, colorectal cancer, non-small cell lung carcinoma, pancreatic ductal adenocarcinoma |
Allist Pharmaceuticals, Inc. |
Recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT04720976 |
Mar 2021 → Dec 2023 |
non-small cell lung carcinoma |
Allist Pharmaceuticals, Inc. |
Completed
|
No outcome recorded
|
| Phase 31 trial |
|
Phase 3
|
NCT06416410 |
Aug 2024 → Sep 2026 overdue |
non-small cell lung carcinoma |
Allist Pharmaceuticals, Inc. |
Recruiting
|
No outcome recorded
|